We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Researchers Present Definitive Molecular Structure of mTORC1

By LabMedica International staff writers
Posted on 27 Dec 2015
By combining cryoelectron microscopy with X-ray crystallographic data, researchers have been able to define the structural architecture of the protein complex mTORC1 (mammalian target of rapamycin complex 1).

Mammalian target of rapamycin (mTOR) is a master regulator of protein synthesis that under ordinary conditions induces cells to grow and divide. More...
In situations of severe nutrient deprivation mTOR prevents protein synthesis so that the cell can conserve energy. However, in cancer cells the mTOR pathway does not function correctly and signals tumor cells to grow, divide, undergo metastasis, and invade new, healthy tissues. Functionally, mTOR is the catalytic subunit of two structurally distinct complexes: mTORC1 and mTORC2. Both complexes localize to different subcellular compartments, thus affecting their activation and function.

MTOR complex 1 (mTORC1) is composed of the proteins mTOR, regulatory-associated protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 (MLST8), and the non-core components PRAS40 and DEPTOR. This complex functions as a nutrient/energy/redox sensor and controls protein synthesis. The activity of mTORC1 is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids (particularly leucine), and oxidative stress.

The extremely large size of the mTORC1 complex has so far prevented researchers from being able to resolve its structure. However, in a study published in the December 17, 2015, online edition of the journal Science, investigators from the University of Basel (Switzerland) described combining cryo-electron microscopy at 5.9 angstrom [1 angstrom = 0.1 nm] resolution with crystallographic studies of Chaetomium thermophilum Raptor at 4.3 angstrom resolution.

The structural details established during this study served to explain how FKBP (FK506 binding protein)-rapamycin and architectural elements of mTORC1 limited access to a recessed active site in the complex. Consistent with a role in substrate recognition and delivery, the conserved N-terminal domain of Raptor was juxtaposed with the kinase active site.

"The partner proteins of mTOR have already been identified in earlier biochemical studies", said senior author Dr. Timm Maier, professor of structural biology at the University of Basel. "However, it has remained unclear how the proteins interact precisely. But it does not make sense to examine the individual components alone, as the interactions of all the proteins in the complex are critical for its function. The whole is much more than the sum of its parts. Although there is much known about mTORC1, our study revealed surprising new insight. The architecture of this huge protein complex is quite exceptional. We could determine the precise interaction sites of the partner proteins and how they are arranged, and thus elucidate the function of the individual partners."

Related Links:

University of Basel



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.